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The Effect of Non-motor Symptoms on Quality of Life in Parkinson’s Disease
Parkinson’s disease (PD) affects about 1–2% of the population over 
65 years of age and up to 3–5% of people 85 years of age and older.1
As the average age of the population increases, the prevalence of 
PD can be expected to rise. There is increasing awareness that the
non-motor symptoms (NMS) of PD significantly contribute to the
overall burden of the disease, which determines quality of life (QoL).
With this in mind, it is essential to optimise the management of all
aspects of PD. NMS (see Table 1) include neuropsychiatric
complications, autonomic disorders, sleep disturbances and sensory
symptoms. NMS affect the majority of patients during their illness
and, although NMS correlate strongly with advancing disease, they
may precede the onset of motor symptoms by a number of years.2–5
It is increasingly recognised that NMS create a significant burden for
people with PD and affect QoL to a greater extent than motor
features.6–14 Without careful attention, NMS may remain undiagnosed
and untreated. A recent international survey showed that up to 62%
of NMS in PD might remain undeclared to healthcare professionals
because patients are either embarrassed or unaware that their
symptoms are linked to PD.15 Using a screening tool can help to
identify the problem. For example, in a study using the NMS
Questionnaire (NMSQ), PD patients reported nine to 12 different NMS
in their clinic visit, many of which had not been discussed with the
doctor before being flagged by the NMSQ.16
Scale and Impact of the Problem of 
Non-motor Symptoms in Parkinson’s Disease
NMS occur in up to 90% of patients with PD during their disease
course.5 Shulman et al. studied 99 patients with PD without dementia
and reported that over half had at least two NMS and 25% had more
than three.5 In a more recent study of 49 patients with PD, McKinlay et
al. found that 77% reached the cut-off for one or more NMS, while 46%
had three or more.10 The PRIAMO study of 1,072 consecutive patients
with PD found that 98.6% of patients reported at least one NMS.6 The
frequency of NMS increased with disease severity, and patients with
cognitive impairment had more NMS than those without. In the latest
validation study of the Non-Motor Symptoms Scale (NMSS) in PD, only
two of 411 patients reported no NMS.17 The same study suggested that
there is a close and robust correlation between the overall burden of
NMS, measured by the NMSS composite score, and QoL, measured by
the Parkinson’s Disease Questionnaire (PDQ-39). The correlation value
(Spearman r=0.7) was stronger than the correlation between QoL and
motor state. This study is one of the first to establish the  close link
between NMS and QoL in a statistical manner in an international study
spanning PD patients across all disease stages.17 Our review focuses
on the impact of common NMS on QoL for patients with PD. 
Neuropsychiatry
Neuropsychiatric symptoms are among the most common NMS in PD,
constitute a major problem in management, cause reduced QoL for
patients and increase care-giver distress.18
Depression and Anxiety
Depression can occur early and may precede motor symptoms. The
rate of depression in community-based samples of patients with PD is
approximately 30–40%.19 Identification of mood disturbances is critical
as it is well known that depression is the most significant predictor of
QoL in patients with PD.7,8,11,13,20,21 Anxiety is relatively under-investigated
in PD, despite being present in up to 55.8% of patients.6
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Schrag et al. assessed determinants of QoL using the PDQ-39 in 
97 patients with PD. They found that depression was the strongest
predictor of QoL impairment and was more important than clinical
features of the disease, postural instability or cognitive function.13
These results were replicated in a larger community-based sample of
233 patients with PD, in which Karlsen et al. found that the variables
most strongly predictive of worse QoL (a higher total score on the
Nottingham Health Profile) were depression, self-reported insomnia
and a low degree of independence.20 Severity of parkinsonism
contributed to a lesser extent. In a study of Indian patients with PD,
Bahari et al. also found that depression (Diagnostic and Statistical
Manual of Mental Disorders III Revision [DMS-III-R]) was the most
significant factor impairing QoL (PD Quality of Life Questionnaire).7
In a cross-sectional study of 190 PD patients, Muslimovic et al. found
that self-reported mood symptoms and axial impairment were the
main determinants of worse QoL (PD Quality of Life Questionnaire)
and that both depression and anxiety were related to QoL to a
similar degree.11 Rahman et al. looked at the relative contributions of
PD symptoms to patient QoL (PDQ-39).22 The psychiatric symptom
cluster accounted for 41.8% of variance of PDQ-39, and depression,
confusion and fatigue symptoms significantly predicted QoL. In
addition, they found that depression (Beck Depression Inventory
[BDI]) accounted for 40.8% of the variance in PDQ-39. Once the
contribution of depression to QoL was taken into account, self-rated
anxiety on the Beck Anxiety Inventory (BAI) accounted for a further
17.0% of the variance in QoL scores. In another study looking at both
depression and anxiety, Carod-Artal et al. found that anxiety
(Hospital Anxiety and Depression Scale—Anxiety [HADS-A]) and
depression (Hospital Anxiety and Depression Scale—Depression
[HADS-D]) both independently predicted QoL (PDQ-39), but the study
did not assess which contributed the most.23
Having a history of depression may be sufficient to lead to worse QoL.
Klepac et al. studied 152 non-demented patients with PD and found
that a history of pre-morbid depression was independently associated
with higher actual levels of depression (BDI) and anxiety (Hamilton
Rating Scale for Anxiety [HAM-A]), poorer sleep (Pittsburg Sleep
Quality Index [PSQI]) and worse QoL (PDQ-39).24 Therefore, if a patient
with PD has a history of depression, he or she may be a good
candidate for early intervention.
Few studies have addressed whether improving mood translates into
improved QoL. Menza et al. treated 52 PD patients with paroxetine,
nortriptyline or placebo for eight weeks and then had a 16-week blind
extension phase. Interestingly, no difference in QoL measures was
found between the three groups. However, those with improvements
in depression demonstrated significant gains in PDQ-8.25 Thus, the
conclusion was that QoL improves in those patients in whom
depression is treated successfully. 
Psychotic Symptoms/Hallucinations
Approximately one-third of chronically treated PD patients suffer from
psychosis,26 and while visual hallucinations are often benign, more
sinister symptoms such as delusions, paranoid ideation and delirium
become more frequent as the disease progresses. Early identification
and management are crucial as psychotic symptoms are a significant
risk factor for nursing home placement and are associated with
higher mortality in advanced stages of PD.27 Psychotic symptoms 
are closely linked to dopaminergic treatment, but drug therapy 
may not be the only cause. Aarsland et al. found that psychotic
symptoms were associated with severe depressive symptoms and
cognitive impairment, but that antiparkinsonian medication type, 
daily dose and treatment duration did not differ between the PD
patients with and without psychosis.28 Several risk factors for the
development of psychotic symptoms have been identified: cognitive
impairment, dementia, increased age, disease duration, disease
severity, depression and sleep disorders.26
Cognitive Impairment
Cognitive dysfunction affects 24% of patients with newly diagnosed
PD,29 while dementia affects up to 80% of PD patients with late-stage
disease.30 The correlation between cognitive impairment and QoL in
patients with PD has been well-established.9,13,21,31,32 Although having
worse cognitive function predicts worse QoL, the relative impact is
less than that of other NMS. Muslimovic et al. demonstrated that
cognitive changes had little impact on functional outcome once the
effect of motor and mood symptoms had been taken into account.11
Co-morbid NMS seem to affect the strength of association between
cognitive impairment and QoL. For example, Klepac et al. found 
an association between cognitive impairment and QoL but only in
patients with lower depression scores; in patients with higher
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depression scores, QoL was poor regardless of cognitive status. The
authors also found that better visual attention/memory and better
visuospatial and executive functioning in non-demented patients with
PD is independently associated with better QoL.33
Sleep Disorders
Sleep disorders are among the most frequent NMS, occurring in up to
90% of people with PD,34,35 and they usually start early in the disease
course. They include restless legs syndrome (RLS), sleep-disordered
breathing, rapid eye movement (REM) sleep behaviour disorder (RBD),
excessive daytime somnolence (EDS) and insomnia. Although it is
intuitive that sleep disorders would have a negative impact on patient
QoL, this has not yet been adequately measured in PD. Interestingly, a
small study of 11 patients with mild PD and seven patients with
severe PD demonstrated that severity of disease did not differentially
affect sleep disturbance.36
Restless Legs Syndrome 
The frequency of RLS in PD is not well established. Study estimates
range from 8 to 20%, but some authors have found no difference in
prevalence between PD patients and controls.37 In a cross-section
analysis of 114 patients with PD, Gomez-Esteban et al. found that QoL
as measured on the PDQ-39 did not differ between the PD patients
with and without RLS.37 Interestingly, in studies of patients with RLS but
without PD, it has been demonstrated that RLS has a substantial
negative impact on QoL – as much as other chronic neurological
conditions such as stroke and PD.38
Rapid Eye Movement Sleep Behaviour Disorder
RBD is a frequently observed sleep disorder in people with PD,
occurring in about one-third of patients, and may precede the
development of cardinal motor features.2 The problem is not
benign, as self-injury and injury to the partner can occur during
attacks. Little literature exists examining the effect of RBD on QoL.
In a study comparing PD patients with and without RBD, Postuma et
al. found that the groups did not differ in overall QoL (PDQ-39).
However, the RBD group had lower ‘general health’ and ‘emotional’
subscores on the SF-36.39
Excessive Daytime Somnolence
EDS affects 15–50% of people with PD40 and may be a pre-clinical
marker of the disease.3 Neuronal degeneration of the suprachiasmatic
nucleus, which regulates the internal rhythm between sleep and
wakefulness, may explain the early occurrence of EDS.3 Additional
contributing factors may include nocturnal sleep disruption and
antiparkinsonian medications. Although it is intuitive that effectively
identifying and managing EDS would improve patient QoL, there is
currently little evidence.
Insomnia
The prevalence of insomnia in PD varies from 18 to 88% depending on
the definitions used and the population assessed.20,41,42 Many factors
associated with PD may contribute to insomnia, including RLS,
imbalance of REM and non-REM sleep, altered biological rhythms,
altered breathing, effect of antiparkinsonian medications, motor
fluctuations, autonomic impairments, stiffness, pain and difficulty
turning in bed.34 Insomnia and depressive symptoms have been found
to be most strongly predictive of impaired overall QoL.12,20 In a study of
102 PD patients living at home, Caap-Ahlgren and Dehlin found a
strong correlation between insomnia and each of depression and
pain. In addition, greater insomnia was associated with increased
disease severity, and those patients with insomnia had worse QoL
scores as measured by SF-36 than those without insomnia.34
However, some authors have found only small correlations between
sleep and QoL scores.43
Fatigue
Although fatigue is a prominent problem for many patients, occurring
in up to 50%,44,45 it is poorly understood and often overlooked.46 It is
the single most important reason cited by Americans for obtaining
disability insurance payments for their PD.47 Although often reported
to be associated with depression, there is evidence that fatigue is a
prominent feature of PD independently of depressive symptoms.45,48
Herlofson and Larsen assessed 66 PD patients without depression or
dementia using the Fatigue Severity Scale (FSS). Half of the sample
had fatigue, and those with fatigue had more advanced disease and
tended to have longer duration of disease.45 Fatigue can also be a side
effect of antiparkinsonian medications; however, in a study of non-
demented, non-depressed, newly diagnosed PD patients with mild
motor dysfunction, fatigue was found to be an early problem and not
related only to medication.49
Studies have shown that PD patients have more fatigue and poorer QoL
than healthy individuals or people with other chronic conditions, such
as diabetes.50 In addition, PD patients with fatigue have significantly
worse QoL than PD patients without fatigue.45 Using different measures
of fatigue, Havlikova et al., Rahman et al. and Qin et al. each found that
presence of fatigue predicted worse QoL (PDQ-39).12,22,44
The disability suffered by patients due to fatigue is significant: over
half of patients with PD list fatigue as one of their three most
disabling symptoms, and one-third list fatigue as the single most
disabling symptom.51 In a study from The Netherlands, 43% of 90
non-depressed patients with PD suffered from fatigue and 15%
rated fatigue as their worst symptom.52
Sensory Symptoms
PD was previously thought to be a primary motor disorder. It has now
become widely accepted that sensory symptoms, including pain,
hyposmia and visual dysfunction, are prevalent in patients with PD
and have a negative impact on QoL.
Pain
Pain affects up to 74% of PD patients53 and, due to its heterogenous
aetiology, presents a complex diagnostic and management issue. Pain
can be secondary to PD (dystonic pain or akathitic discomfort), due 
to co-morbid conditions (diabetic neuropathy) or a result of PD
symptoms aggravating underlying non-PD pain (abnormal gait
worsening osteoarthritic hip pain). 
Regardless of aetiology, pain negatively affects QoL in patients with
PD.22,53,54 Roh et al. studied 82 Korean patients with PD using the SF-36,
breaking it down into the mental and physical component scores
(MCS and PCS, respectively).53 Pain, measured on a visual analogue
scale (VAS), showed moderate correlation with decreased QoL, worse
Unified Parkinson Disease Rating Scale (UPDRS) III, more severe
depression and more somatic complaints. VAS and depression had
the most detrimental impact on PCS and MCS, respectively. Pain was
significantly influenced by depression and motor symptoms, as also
shown by Karlsen et al.20
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In a study assessing chronic pain in PD, Negre-Pages et al. found the
prevalence to be 62%.55 The same study found that patients with PD-
related pain had worse QoL (PDQ-39) than PD patients with non-
PD-related pain and PD patients with no pain.55 Patients with PD have
less frequent analgesic consumption than non-PD patients, which
may reflect under-reporting or under-treatment.55
Olfactory Disturbance
Olfactory dysfunction may affect up to 90% of PD patients and has
been shown to be a pre-clinical marker for the disease.3,56,57 There is a
paucity of research on the impact of olfactory dysfunction suffered by
patients with PD.
Autonomic Dysfunction
Autonomic dysfunction is an important NMS of PD and includes a
range of problems such as urinary, cardiovascular, sexual and
gastrointestinal symptoms. These problems can occur early in the
disease course and are not necessarily related to disease duration or
severity.58,59 Autonomic symptoms occur significantly more often in
patients with PD than in age-matched controls and have a major
impact on the daily life of those with PD. In a study of 141 hospitalised
patients with PD, 50% rated the effect of autonomic symptoms as ‘a
lot’ or ‘very much’.59
Bladder Dysfunction
Bladder dysfunction, including urgency, nocturia, frequency and
incontinence, is reported more commonly and has a greater impact
on the daily life of patients with PD than in age-matched controls.59
The impact can be severe: urogenital infections are a frequent cause
of death in parkinsonism.60
Using a representative sample of a community-living Canadian
population, Pohar and Allyson Jones found that having urinary
incontinence results in an additional burden for the PD patient.61 In a
questionnaire-based assessment of pelvic dysfunction in patients with
PD, Sakakibara et al. found that patients with PD had a significantly
higher frequency of urinary urgency, daytime and night-time frequency,
incontinence, hesitancy, poor stream and straining than the control
group.62 Patients with PD reported more dissatisfaction with bladder
dysfunction than controls. Rahman et al. found that urinary
incontinence had an effect on QoL (PDQ-39) in patients with PD, but the
result was not statistically significant; however, urinary incontinence did
emerge as a predictor of QoL.22
Sexual Dysfunction
Sexual dysfunction is common in PD but no studies have examined
its effect on QoL using validated measures. A decrease in libido,
sexual intercourse and orgasm, and problems with erection and
ejaculation, occur significantly more frequently in patients with PD
than in controls.62 Although one might expect sexual dysfunction to
negatively affect patients, Sakakibara et al.62 found that the rate of
dissatisfaction with sexual dysfunction was not significantly higher
for patients with PD compared with controls.62
Sweating
There is a paucity of work examining the impact of sweating on QoL
in PD, despite studies showing that it affects almost half of
patients.59 Swinn et al. assessed 77 consecutive patients with PD
using a novel questionnaire and found that almost two-thirds
reported a problem with sweating – a significantly higher
proportion than in the controls. Although sweating disturbances
were related to other symptoms of autonomic dysfunction, there
was no association with overall QoL (PDQ-39 and EuroQ-5D). The
responses to the questionnaire highlighted the impact of sweating
on daily life: patients with sweating frequently felt cold/
uncomfortable (33%), had disturbed sleep (29%), had to change
nightwear (8%), were limited in social activities (4%), felt
embarrassed (8%) and felt down (20%).63
Orthostatic Hypotension
Half of patients with PD complain of non-specific symptoms such as
giddiness, transitory defective vision, nausea, cerebral hypoxaemia
and dizziness.60 Loss of consciousness is rare but can lead to serious
injury.60 Orthostatic hypotension is the most frequent cardiovascular
symptom, reported by almost half of hospital inpatients with PD.59,60
Blood pressure not only drops significantly upon rising, but also fails
to normalise again over many minutes. In a study by Magerkurth et
al. of consecutive hospitalised PD patients, orthostatic dizziness had
more impact on the daily lives of patients with PD than on age-
matched controls.59
Dribbling of Saliva
Dribbling of saliva is a frequent complaint in patients with PD,
occurring in 30–74%, and results not only from excess production of
saliva but also from infrequent or impaired swallowing.40,64 Like other
NMS, drooling can pre-date the diagnosis of PD and is often under-
treated.64 In an analysis of 63 PD patients with drooling, 73% had mild
to moderate drooling and 27% had severe or profuse drooling.
Dribbling of saliva had both emotional and social consequences in up
to 77% of patients – and to a significantly greater in patients with
more severe drooling.64
Dysphagia
Nine out of 10 patients with PD develop dysphagia during the course
of their disease.65 The consequences are severe as aspiration
pneumonia is the leading cause of death in this group.66
There are few studies investigating the impact of dysphagia on QoL
in patients with PD. Plowman-Prine et al. compared PD patients
with dysphagia versus those without, using swallow-specific QoL
(SWAL-QOL), general QoL (PDQ-39) and depression (BDI) as
outcome measures. Both the dysphagic and non-dysphagic groups
had a mild to moderate reduction in SWAL-QOL, although the
dysphagic group had worse total SWAL-QOL scores. The worse 
the SWAL-QOL score, the worse the general QoL, which is perhaps
not surprising given the overlap of questions in the two measures.
The dysphagic group had significantly worse social function and
mental health than the non-dysphagic group. Depression increased
with worse SWAL-QOL. Interestingly, patient-reported SWAL-QOL
was not related to disease duration or severity, suggesting that
dysphagia is an important issue not only in advanced disease but
throughout all stages of disease.67
Using a semi-structured interview and qualitative analysis in a sample
of 37 patients with PD, Miller et al. found that dysphagia affects not
only the lives of people with PD but also their carers, and swallowing
impairment need not be severe before having a significant impact.68
The consequence of dysphagia is not limited to difficulty chewing and
swallowing, but also applies to activities surrounding mealtimes such
as shopping, preparation and socialisation.68
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Constipation
Constipation is a common NMS of PD and may precede the
development of motor symptoms.69 Magerkurth et al. did not find a
significant difference in prevalence of constipation in hospitalised 
PD patients compared with age-matched healthy controls, but PD
patients more frequently rated the problem as having ‘a lot’ or ‘very
much’ impact on daily life.59 In an outpatient sample of PD patients,
Rahman et al. found that constipation had an effect on QoL scores
only when using less stringent p-values than were set a priori.
However, constipation was found to be a predictor of QoL.22
Conversely, Sakakibara et al. found that PD patients had a significantly
higher frequency of constipation and difficulty in expulsion and had
more dissatisfaction with bowel dysfunction than the control group.62
Conclusion
In summary, NMS are common in patients with PD, although they are
often overlooked. NMS result in a significant burden for people with
PD and negatively affect QoL. Further studies are needed to assess
the effect of treating NMS on improving QoL. n
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